XOMA Royalty (NASDAQ:XOMA) Upgraded at Zacks Research

Key Points

• XOMA Royalty has been upgraded to a "hold" rating by Zacks Research, amidst recent assessments from other analysts indicating varying degrees of optimism about the stock.
• Benchmark has set a target price of $35.00 while HC Wainwright estimates the price at $104.00, indicating a potential for significant price appreciation.
• The company reported an earnings per share (EPS) of $0.48 for the last quarter, surpassing expectations and generating revenue of $13.13 million, which also exceeded analyst projections.

XOMA Royalty (NASDAQ:XOMA - Get Free Report) was upgraded by analysts at Zacks Research to a "hold" rating in a research report issued to clients and investors on Tuesday, August 12th,Zacks.com reports.

Other analysts have also issued research reports about the company. Benchmark began coverage on XOMA Royalty in a report on Thursday, April 17th. They issued a "buy" rating and a $35.00 price target for the company. HC Wainwright reaffirmed a "buy" rating and issued a $104.00 price target on shares of XOMA Royalty in a research report on Wednesday, May 28th. Finally, Wall Street Zen upgraded XOMA Royalty from a "hold" rating to a "buy" rating in a report on Monday, August 11th. Two equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $69.50.

XOMA Royalty Trading Up 1.2%

XOMA traded up $0.40 on Tuesday, reaching $32.46. 64,129 shares of the company traded hands, compared to its average volume of 44,093. The company has a market cap of $392.38 million, a P/E ratio of -20.94 and a beta of 1.00. The company has a quick ratio of 4.88, a current ratio of 4.88 and a debt-to-equity ratio of 1.41. XOMA Royalty has a one year low of $18.35 and a one year high of $35.00. The firm has a fifty day simple moving average of $26.68 and a two-hundred day simple moving average of $24.41.

XOMA Royalty (NASDAQ:XOMA - Get Free Report) last issued its earnings results on Wednesday, August 13th. The biotechnology company reported $0.48 EPS for the quarter, topping analysts' consensus estimates of ($0.12) by $0.60. XOMA Royalty had a negative net margin of 27.57% and a positive return on equity of 2.63%. The business had revenue of $13.13 million for the quarter, compared to analyst estimates of $9.39 million. As a group, equities research analysts expect that XOMA Royalty will post -1.41 earnings per share for the current year.

Institutional Investors Weigh In On XOMA Royalty

Hedge funds have recently added to or reduced their stakes in the business. Opaleye Management Inc. raised its stake in shares of XOMA Royalty by 0.8% during the 2nd quarter. Opaleye Management Inc. now owns 255,087 shares of the biotechnology company's stock valued at $6,428,000 after buying an additional 2,044 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of XOMA Royalty by 9.1% in the second quarter. Geode Capital Management LLC now owns 203,601 shares of the biotechnology company's stock worth $5,132,000 after buying an additional 16,929 shares during the last quarter. Woodline Partners LP grew its holdings in XOMA Royalty by 7.9% during the first quarter. Woodline Partners LP now owns 168,550 shares of the biotechnology company's stock worth $3,359,000 after acquiring an additional 12,284 shares during the period. Stonepine Capital Management LLC raised its position in XOMA Royalty by 17.2% during the second quarter. Stonepine Capital Management LLC now owns 152,143 shares of the biotechnology company's stock valued at $3,834,000 after acquiring an additional 22,330 shares in the last quarter. Finally, Eversept Partners LP lifted its holdings in XOMA Royalty by 1.2% in the fourth quarter. Eversept Partners LP now owns 95,417 shares of the biotechnology company's stock valued at $2,508,000 after acquiring an additional 1,128 shares during the period. 95.92% of the stock is owned by hedge funds and other institutional investors.

XOMA Royalty Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.